NanoViricides, Inc.

Climate Impact & Sustainability Data (2012-07-01 to 2012-06-30, 2018, 2019)

Limited expenditures on socially conscious projects such as "Neglected Tropical Diseases" (NTDs), and "Bio-defense" projects to the extent that participatory funding from third parties is available.

Appointed Mr. Stanley Glick, CPA, as an independent Director of the Company and the Chairman of its Audit Committee.

Weak financial markets resulted in substantial limitations on capital-raising efforts.
Scaled down programs, particularly the cGMP manufacturing facility program, to meet financial challenges.

Scaled down programs to meet financial challenges.
Aggressively seeking cash-preserving means of financing for the new lab and cGMP capability (SBA loans, other loans, alternate financing vehicles, equity-based financing).

Short-term Goals:

Fiscal constraints leading to R&D staffing reduction (25% in the last few years), lengthening the timeline to begin human clinical trials.
Non-compliance with NYSE’s continued listing requirements due to insufficient members on the audit committee.
Limited experience in drug development and conducting clinical trials, necessitating outsourcing.
Limited manufacturing experience and lack of sales and marketing personnel.
Dependence on TheraCour Pharma, Inc. for core technology and manufacturing.
Difficulty in attracting and retaining highly skilled personnel.
Conflicts of interest among officers, directors, and stockholders.

Focused efforts on the HerpeCide program, prioritizing the shingles indication.
Rescinded resignation of Dr. Kulkarni from the audit committee and actively interviewing candidates for additional independent directors.
Outsourcing clinical trials to third parties.
Owning a cGMP-capable manufacturing facility to potentially enable initial market entry.
Negotiating with TheraCour Pharma, Inc. for additional licenses.
Implementing a continuous training program for employees.
Establishing a Search Committee to find additional independent directors.
Maintaining a majority independent Board of Directors, a fully independent Compensation Committee, and a fully independent Audit Committee.

Short-term Goals:

Finalize human clinical trials designs for Phase I and Phase II trials for NV-HHV-101 for topical treatment of shingles rash.
Engage a contract Clinical Research Organization for conducting the human clinical trials.
Complete the IND-enabling studies, and prepare appropriate reports.
Complete manufacture of cGMP-compliant drug substance and drug products in quantities sufficient for anticipated human clinical trials as designed.
Submit an IND-application to the US FDA, or an appropriate international regulatory agency.
Initiate and conduct Phase I human clinical trials, to determine safety and tolerability of NV-HHV-101 in human subjects.
If possible, initiate Phase II human clinical trials to determine effectiveness of NV-HHV-101 in controlling shingles rash and to study the effectiveness of NV-HHV-101 regarding shingles pain.

Fiscal constraints leading to a 40% reduction in R&D staffing at affiliates, lengthening the timeline to begin human clinical trials.

Focused efforts primarily on the HerpeCide program, prioritizing the shingles indication to maximize return on investment and shareholder value.